 |
|
|
| |
Vaniprevir (MK-7009) in Treatment-Experienced Genotype (GT) 1 HCV-Infected Patients Demonstrates Time-Dependent Pharmacokinetics (PK)
|
| |
| |
Reported by Jules Levin
APASL- Asian Pacific Association Liver Week
23rd Conference June 6 - 10, 2013, Singapore
Gao W, Caro L, Du L, Han L, Anderson M, Hwang P, Bhanja S, Su J, Mobashery N
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
AASLD 2011: A Phase 2b Study of MK-7009 (vaniprevir) in Patients with Genotype 1 HCV Infection Who HaveFailed Previous Pegylated Interferon and Ribavirin Treatment........http://www.natap.org/2011/AASLD/AASLD_55.htm
AASLD Nov 3 2008: Safety, Tolerability and Antiviral Activity of MK-7009, a Novel
AASLD Nov 5-8 2011: Safety and Efficacy of Vaniprevir (MK-7009) in Combination with Peg-interferon a-2a (Peg-IFN)/Ribavirin (RBV) in Genotype 1 Treatment-Experienced HCV-Infected Japanese Patients......http://www.natap.org/2011/AASLD/AASLD_68.htm
|
| |
|
|
|
|
|
